tiprankstipranks
Trending News
More News >
Venus Remedies Limited (IN:VENUSREM)
:VENUSREM
India Market
Advertisement

Venus Remedies Limited (VENUSREM) AI Stock Analysis

Compare
1 Followers

Top Page

IN:VENUSREM

Venus Remedies Limited

(VENUSREM)

Rating:68Neutral
Price Target:
₹503.00
▲(9.04% Upside)
Venus Remedies Limited's strong financial performance is the most significant factor, reflecting robust revenue growth, profit margins, and cash flow management. The technical analysis indicates a lack of bullish momentum, which slightly offsets the financial strengths. The valuation suggests the stock is reasonably priced, contributing positively to the overall score.

Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)

Venus Remedies Limited Business Overview & Revenue Model

Company DescriptionVenus Remedies Limited (VENUSREM) is a globally recognized pharmaceutical company specializing in the research, development, and manufacturing of a wide range of generic and branded pharmaceutical products. The company focuses on several key therapeutic areas, including oncology, anti-infectives, and critical care medications, catering to both domestic and international markets. Venus Remedies is known for its innovative approach to drug delivery systems and commitment to quality standards, which has earned it a strong presence in over 70 countries worldwide.
How the Company Makes MoneyVenus Remedies Limited generates revenue primarily through the sale of its pharmaceutical products, which include both generic and branded medications. The company's revenue streams are diversified across various therapeutic segments, with significant contributions coming from oncology, anti-infectives, and critical care drugs. Venus Remedies leverages its extensive distribution network and strong partnerships with healthcare providers, hospitals, and pharmacies to ensure wide market reach. Additionally, the company's focus on research and development enables it to introduce new and innovative products, contributing to sustained growth and competitive advantage in the pharmaceutical industry.

Venus Remedies Limited Financial Statement Overview

Summary
Venus Remedies Limited shows strong financial performance with consistent revenue growth, robust profit margins, and effective cash flow management. The company maintains financial stability with a low reliance on debt and a solid equity base, indicating a solid financial foundation and potential for sustained growth.
Income Statement
78
Positive
Venus Remedies Limited has demonstrated strong revenue growth over the years, with a significant increase from 2020 to 2025. The company maintains a healthy Gross Profit Margin, indicating efficient production and cost management. The Net Profit Margin has improved significantly compared to earlier losses, reflecting enhanced operational efficiency and profitability. The EBIT and EBITDA margins are solid, showcasing robust earnings performance before interest, taxes, and non-cash expenses.
Balance Sheet
75
Positive
The company displays a strong equity position with a high Equity Ratio, suggesting financial stability and a low reliance on debt. The Debt-to-Equity Ratio is favorable, indicating low financial leverage and reduced risk of financial distress. Return on Equity has shown consistent improvement, reflecting effective use of shareholders' equity in generating profits.
Cash Flow
82
Very Positive
Venus Remedies Limited exhibits strong cash flow performance, with a significant positive Free Cash Flow trend, indicating good cash generation after capital expenditures. The Operating Cash Flow to Net Income Ratio is robust, highlighting efficient conversion of earnings into cash. There is a significant increase in Free Cash Flow over the years, underscoring the company's strong cash-generating capabilities.
BreakdownTTMDec 2025Dec 2023Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.48B6.48B5.56B5.91B5.99B5.48B
Gross Profit1.75B1.66B2.25B2.18B2.00B1.96B
EBITDA820.40M944.10M605.10M711.80M625.77M545.57M
Net Income348.50M453.20M265.70M284.91M407.24M617.65M
Balance Sheet
Total Assets0.007.16B6.01B6.27B5.80B5.56B
Cash, Cash Equivalents and Short-Term Investments1.34B1.64B749.20M838.05M453.11M288.79M
Total Debt0.0016.90M422.90M413.25M428.45M513.18M
Total Liabilities-4.94B1.55B1.41B1.39B1.39B1.56B
Stockholders Equity4.94B5.61B4.60B4.88B4.40B4.00B
Cash Flow
Free Cash Flow0.00812.90M288.02M278.40M272.94M1.25B
Operating Cash Flow0.00909.20M366.20M372.85M410.01M1.33B
Investing Cash Flow0.00-807.90M-508.30M-72.09M-166.26M557.16M
Financing Cash Flow0.00-9.50M-5.70M-10.83M-94.77M-1.62B

Venus Remedies Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price461.30
Price Trends
50DMA
486.04
Negative
100DMA
429.78
Positive
200DMA
368.32
Positive
Market Momentum
MACD
-8.15
Positive
RSI
41.62
Neutral
STOCH
27.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Negative. The current price of 461.3 is below the 20-day moving average (MA) of 476.52, below the 50-day MA of 486.04, and above the 200-day MA of 368.32, indicating a neutral trend. The MACD of -8.15 indicates Positive momentum. The RSI at 41.62 is Neutral, neither overbought nor oversold. The STOCH value of 27.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
₹6.18B11.48
9.15%88.32%
62
Neutral
₹6.16B2.97
-68.96%-30.30%
57
Neutral
₹6.32B21.21
37.51%122.56%
54
Neutral
₹4.71B47.02
0.29%-9.90%33.18%
54
Neutral
₹3.65B38.50
-3.36%-47.58%
51
Neutral
$7.95B-0.40-41.67%2.21%22.29%-1.85%
43
Neutral
₹3.29B30.02
-3.41%-3028.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:VENUSREM
Venus Remedies Limited
461.30
104.45
29.27%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
102.00
-40.20
-28.27%
IN:KILITCH
Kilitch Drugs (India) Limited
372.35
39.62
11.91%
IN:MEDICAMEQ
Medicamen Biotech Limited
351.15
-77.37
-18.06%
IN:NECLIFE
Nectar Lifesciences Ltd.
14.66
-37.03
-71.64%
IN:ZIMLAB
Zim Laboratories Ltd.
74.20
-45.50
-38.01%

Venus Remedies Limited Corporate Events

Venus Remedies Announces AGM Notice Publication
Jul 11, 2025

Venus Remedies Limited has announced a newspaper publication regarding its Annual General Meeting (AGM) notice. This announcement is part of the company’s regulatory compliance under Regulation 30 of the Listing Obligations and Disclosure Requirements (LODR). The publication ensures that stakeholders are informed about the AGM, which is a critical event for discussing the company’s performance and future strategies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025